By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Allergan Inc. 

2525 Dupont Drive

Irvine  California  92612  U.S.A.
Phone: 714-246-4500 Fax: n/a


Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have approximately 11,100 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. For the year ending 2012, our total product net sales totaled $5.5 billion, a 10 percent increase over 2011. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate more than six decades of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to:

Key Statistics

Ownership: Public

Web Site: Allergan
Employees: 11,100
Symbol: AGN



Elan Pharmaceuticals 

CeNes Pharmaceuticals (U.S.) 

PanVera LLC 

Pharmagene Laboratories Limited  Phase ZERO(TM) products and services.

Acadia  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Acadia  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Acadia  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Company News
Allergan (AGN) Slams Down $250 Million+ for Rights to Merck & Co. (MRK)'s Migraine Drugs 7/7/2015 6:10:11 AM
Allergan (AGN) Forks Over $125 Million+ for Bay Area Medtech Firm Oculeve 7/6/2015 5:47:23 AM
Allergan (AGN) To Host Second Quarter 2015 Earnings Conference Call And Webcast 6/30/2015 7:52:52 AM
CEO Brent Saunders Says Allergan (AGN) Remains Committed To Irvine Despite Sale 6/25/2015 6:56:57 AM
Allergan (AGN) CEO Bullish Over Keeping Generics Unit But Open to Other “Transformative” Deals 6/18/2015 6:39:42 AM
Double Chin Drug Is A Perfect Fit For Botox-Maker Allergan (AGN). But Is It Too Pricey? 6/18/2015 6:39:27 AM
Allergan (AGN) Coughs Up $2.1 Billion for Double-Chin Drugmaker Kythera (KYTH) 6/17/2015 5:56:07 AM
Richter And Allergan (AGN) Announce FDA Has Extended The Review Period For Cariprazine To September 2015 6/16/2015 6:09:59 AM
Actavis (ACT) Officially Changes Name to Allergan (AGN) 6/15/2015 6:21:57 AM
FDA Warns Allergan (AGN) Over Marketing of Seri Scaffold 6/11/2015 7:15:24 AM